Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire Expects Intuniv Launch In Mid-’09, As Firm’s ADHD Share Tops 30%

Executive Summary

Shire plans to launch its nonstimulant ADHD candidate Intuniv in the second half of 2009, though new studies may be required to gain FDA approval

You may also be interested in...



Strattera Cleared For Longer Use In ADHD Kids

Trial data could reassure doctors about treating as needed, Lilly says.

Vyvanse’s Long Shadow: Launch To Decide Fate Of Two Other Shire Drugs

Shire is keeping two pending NDAs for new attention deficit hyperactivity disorder treatments in a sort of limbo while it waits to see if the high expectations for the launch of its d-amphetamine prodrug Vyvanse are fulfilled

Shire Daytrana ADHD Patch To Launch In Early July With Some Class Labeling

Shire and manufacturing partner Noven expect an early July launch for Daytrana, the first transdermal patch for the treatment of attention deficit/hyperactivity disorder to receive FDA approval

UsernamePublicRestriction

Register

PS049368

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel